CN204405680U - Detect the test strips of Procalcitonin - Google Patents
Detect the test strips of Procalcitonin Download PDFInfo
- Publication number
- CN204405680U CN204405680U CN201520103122.3U CN201520103122U CN204405680U CN 204405680 U CN204405680 U CN 204405680U CN 201520103122 U CN201520103122 U CN 201520103122U CN 204405680 U CN204405680 U CN 204405680U
- Authority
- CN
- China
- Prior art keywords
- procalcitonin
- test strips
- antibody
- binding regions
- analyte binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 34
- 108010048233 Procalcitonin Proteins 0.000 title claims abstract description 28
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 title claims abstract description 28
- 238000001514 detection method Methods 0.000 claims abstract description 41
- 239000000463 material Substances 0.000 claims abstract description 39
- 229910052761 rare earth metal Inorganic materials 0.000 claims abstract description 39
- 150000002910 rare earth metals Chemical class 0.000 claims abstract description 37
- 239000002096 quantum dot Substances 0.000 claims abstract description 36
- 239000012491 analyte Substances 0.000 claims abstract description 31
- 238000003908 quality control method Methods 0.000 claims abstract description 16
- 241001529936 Murinae Species 0.000 claims abstract description 4
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- 239000002245 particle Substances 0.000 claims description 12
- 239000004005 microsphere Substances 0.000 claims description 9
- YBNMDCCMCLUHBL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-pyren-1-ylbutanoate Chemical compound C=1C=C(C2=C34)C=CC3=CC=CC4=CC=C2C=1CCCC(=O)ON1C(=O)CCC1=O YBNMDCCMCLUHBL-UHFFFAOYSA-N 0.000 claims description 3
- 229910004613 CdTe Inorganic materials 0.000 claims description 3
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 claims description 3
- GPXJNWSHGFTCBW-UHFFFAOYSA-N Indium phosphide Chemical compound [In]#P GPXJNWSHGFTCBW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011806 microball Substances 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 5
- 238000004587 chromatography analysis Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000000523 sample Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 13
- 239000012530 fluid Substances 0.000 description 12
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 238000013016 damping Methods 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 239000003365 glass fiber Substances 0.000 description 8
- 229910052693 Europium Inorganic materials 0.000 description 7
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 7
- 229920006267 polyester film Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229910052747 lanthanoid Inorganic materials 0.000 description 4
- 150000002602 lanthanoids Chemical class 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 229910052692 Dysprosium Inorganic materials 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229910052779 Neodymium Inorganic materials 0.000 description 3
- 229910052772 Samarium Inorganic materials 0.000 description 3
- 229910052771 Terbium Inorganic materials 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 3
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- GHXRKGHKMRZBJH-UHFFFAOYSA-N boric acid Chemical compound OB(O)O.OB(O)O GHXRKGHKMRZBJH-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000004879 turbidimetry Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910052765 Lutetium Inorganic materials 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- 229910052773 Promethium Inorganic materials 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 229910001940 europium oxide Inorganic materials 0.000 description 1
- AEBZCFFCDTZXHP-UHFFFAOYSA-N europium(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Eu+3].[Eu+3] AEBZCFFCDTZXHP-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
The utility model provides a kind of test strips detecting Procalcitonin, it is characterized in that, comprise the ingredient that following order overlaps successively: for the sample reception district of sample reception, be coated with by the first analyte binding regions of the first antibody of quantum dot-labeled anti-Procalcitonin, be coated with the second analyte binding regions of the first antibody of the anti-Procalcitonin marked by rare-earth luminescent material, there is the sample detection district of spaced detection zone and quality control band, wherein said detection zone is fixed with the second antibody of anti-Procalcitonin, described quality control band is fixed with the antibody of against murine IgG, and suction zones.The fluorescence immune chromatography reagent card of quantitative detection Procalcitonin provided by the utility model can have the advantage of high sensitivity, low error range simultaneously.
Description
Technical field
The utility model relates to a kind of test strips detecting Procalcitonin.
Background technology
Procalcitonin is the precursor glycoprotein of hormone calcitonin.At present, in the world using Procalcitonin as the monitoring index evaluating clinical infection degree and serious disease.It is generally acknowledged, the biological effect of Procalcitonin is mainly: the effect of secondary inflammatory factor, the effect of chemotactic factor (CF), anti-inflammatory and protective effect etc.Inflammatory reaction is after about 3 hours, and the level of Procalcitonin in blood plasma raises, and within 6-8 hour, reach mxm., but when autoimmunity, allergy and virus infections, Procalcitonin can not raise, and therefore can distinguish viral and germ sexuality dye, direction of medication usage.Bacteriological infection person Serum Procalcitonin Concentrations and the positive correlation of the infection order of severity, Procalcitonin Concentrations declines and then points out disease relapse.Procalcitonin Half-life in vivo is 20-24 hour, can be used for the course of disease and the prognosis of clinical monitoring bacteriological infection and septicemia.
For the detection of Procalcitonin, detection method conventional at present comprises: euzymelinked immunosorbent assay (ELISA), chemoluminescence method, latex enhancing immune turbidimetry, colloidal gold immunity chromatography, fluorescence immune chromatography method etc.Euzymelinked immunosorbent assay (ELISA) and chemoluminescence method detection sensitivity high, can accurate quantitative analysis be realized, but it is consuming time long, and this instant mensuration of single increment cannot be carried out.Though latex enhancing immune turbidimetry can realize high flux screening, due to the restriction of methodology itself, its detection sensitivity is lower, cannot carry out Accurate Measurement to low value sample.Colloidal gold immunity chromatography is simple to operate, without the need to special instrument and equipment, but can only realize sxemiquantitative.In fluorescence immune chromatography method, though organic fluorescent compounds such as fluorescein isothiocyanate (fitc), the rhodamine fluorescent dye etc. of tradition application have very high sensitivity in aqueous, but during the biological sample immune analysis determination such as serum, body fluid, cell for complexity after its labelled antibody or antigen, once the substrate concentration to be checked in sample in low concentration of water at ordinary times, the concentration of coexistent impurity will be much higher than substrate concentration to be checked.Now, the coexistent impurity reasons for its use fluorescence of high concentration will cause serious interference to the fluorometric assay of immune product, and then significantly reduces the sensitivity of fluorescence immunoassay, this greatly limits its application in clinical diagnosis field.
A kind of test strip that can realize Procalcitonin Accurate Measurement is lacked in prior art.Therefore, need to provide a kind of novel procalcitonin detection test strip.
technical scheme
On the one hand, the utility model provides a kind of test strips detecting Procalcitonin, it is characterized in that, comprises the ingredient that following order overlaps successively:
A) for the sample reception district of sample reception,
B) be coated with by the first analyte binding regions of the first antibody of quantum dot-labeled anti-Procalcitonin,
C) the second analyte binding regions of the first antibody of the anti-Procalcitonin marked by rare-earth luminescent material is coated with,
D) have the sample detection district of spaced detection zone and quality control band, wherein said detection zone is fixed with the second antibody of anti-Procalcitonin, described quality control band is fixed with the antibody of against murine IgG, and
E) suction zones.
In one embodiment, described test strips comprises base plate further, and wherein said sample reception district, the first analyte binding regions, the second analyte binding regions, sample detection district and suction zones are bonded on base plate and also sequentially overlap successively.
In one embodiment, described quantum dot is microspheres form and has the particle size range of 2nm-30nm, and described quantum dot is selected from following group: CdTe, CdSe, PbSe, InP and GaN.
In one embodiment, described second analyte binding regions is coated with microballoon further, wherein said micro-ball load has described rare-earth luminescent material and described first antibody.
In one embodiment, the particle size of described microballoon is 50nm-400nm.
In one embodiment, the particle size of described microballoon is 100nm-300nm.
In one embodiment, the particle size of described microballoon is 100nm or 300nm.
In one embodiment, be interposed between 0.3cm to 0.5cm between described detection zone and described quality control band.
In one embodiment, the width of described test strips is between 0.2cm to 0.5cm.
beneficial effect
The test strips of detection Procalcitonin provided by the utility model has high sensitivity simultaneously, the range of linearity is good, and the advantage of low error range.
Utility model content
technical matters
Accompanying drawing explanation
The side-looking structural representation of Fig. 1 test strips of the present utility model.
The plan structure schematic diagram of Fig. 2 test strips of the present utility model.
Reference numeral:
1-sample reception district, 2-first analyte binding regions, 3-second analyte binding regions, 4-sample detection district, 5-suction zones, 6-base plate, 7-quantum dot (microballoon), 8-rare-earth luminescent material, 9-detection zone and 10-quality control band.
Embodiment
Hereinafter come with reference to the accompanying drawings to describe illustrative embodiments in more detail.Described accompanying drawing is used for illustrating the utility model, but not is limited.
Fig. 1 is the side-looking structural representation of test strips of the present utility model.
As shown in Figure 1, the test strips be arranged on base plate 6 comprises analyte binding regions 3, analyte binding regions 2, second, sample reception district 1, first, sample detection district 4 and suction zones 5.
Sample reception district 1 for receiving sample, its can by being selected from glass fibre element film or polyester film, cotton fine material makes, be preferably made up of glass fibre element film.The effect of sample filtering can be played by sample reception district 1.Such as, when detected sample is blood plasma, serum, sample reception district 1 can graininess insolubles in filtered sample, removes impurity interference unnecessary when detecting thus, improves and detect degree of accuracy.
First analyte binding regions 2 is coated with the first antibody of the anti-Procalcitonin marked by quantum dot 7.Quantum dot is made up of semiconductor material, stable diameter at the nano particle of 2nm-30nm, usually present microspheroidal.The electronics of quantum dot and hole are by quantum confinement, and continuous band structure becomes the discrete energy levels structure with molecular characterization, so quantum dot can emitting fluorescence after being excited.Quantum dot is adopted to carry out degree of accuracy and the sensitivity that labelled antibody can improve detection greatly.In one embodiment, described quantum dot has the particle diameter of 2nm-30nm.In a preferred embodiment, described quantum dot has the particle diameter of 2nm-20nm.In a preferred embodiment, described quantum dot has the particle diameter of 5nm-20nm.In one embodiment, described quantum dot is II-VI group quantum dot (as CdTe, CdSe etc.).In another embodiment, described quantum dot is iii-v quantum dot (as InP, GaN etc.).In another embodiment, described quantum dot is group IV-VI quantum dot (as PbSe etc.).
Second analyte binding regions 3 is coated with the first antibody of the anti-Procalcitonin marked by rare-earth luminescent material 8.In test strips of the present utility model, the first antibody being coated on the anti-Procalcitonin on the first analyte binding regions 2 and the second analyte binding regions 3 is identical antibody, and difference is only that it is marked by quantum dot 7 and rare-earth luminescent material 8 respectively.
In the utility model, term " mark " comprises employing chemistry or physical method makes the first antibody of anti-Procalcitonin directly be connected with quantum dot and rare-earth luminescent material.But mark also can be completed by alternate manner, the first antibody of such as rare-earth luminescent material and anti-Procalcitonin is by such as embedding or the mode of load on microballoon reach the object of " mark " simultaneously.Therefore, in one embodiment, the second analyte binding regions 3 can have microballoon (not shown) further, on described microballoon, embedding or load have the first antibody of rare-earth luminescent material and anti-Procalcitonin simultaneously.In one embodiment, embedding or can have chemistry between the rare-earth luminescent material of load on described microballoon and the first antibody of anti-Procalcitonin and connect, such as, be present on described microballoon with the form of the first antibody of the anti-Procalcitonin of rare-earth luminescent material mark.In another embodiment, embedding or can not have chemistry between the rare-earth luminescent material of load on described microballoon and the first antibody of anti-Procalcitonin and connect, namely on described microballoon, embedding or load have to each other without the rare-earth luminescent material of chemistry connection and the first antibody of anti-Procalcitonin.
In one embodiment, described microballoon can be polymer microballoon, such as polystyrene microsphere.In one embodiment, the particle size scope of microballoon, between 50nm-400nm, preferably between 100nm-300nm, is more preferably 100nm or 300nm.
The method preparing rare-earth fluorescent microballoon is that prior art is known, includes but not limited to: investment, namely in the polymerization process of polymer microballoon, adds rare earth material complex; Bonding method, even if there is coordination reaction in the functional group on rare earth element ion and polymer lateral chain obtains rare-earth fluorescent microballoon; And swelling method and cladding process.Latter two method is all on the basis of monodispersed microballoon (as: polystyrene microsphere), by the infiltration of rare earth material complex or the inside or the surface that are coated on microballoon, by controlling reaction conditions, can realize finally preparing the polymer microballoon that monodispersity is good, fluorescence intensity is high, fluorescent stability is good.
Rare-earth luminescent material comprises lanthanide series-lanthanum (La) in the periodic table of chemical element, cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutetium (Lu), and with closely-related two the element-scandiums (Sc) of 15 elements of group of the lanthanides and yttrium (Y) totally 17 kinds of elements.Relative to traditional fluorescent material, rare-earth luminescent material has the spectrum that receptivity is strong, conversion ratio is high and can launch from ultraviolet to infra-red range, has very strong emissive ability in visible region, and the advantages such as stable physical property.In one embodiment, described rare-earth luminescent material is one or several in fluorescent material containing the various lanthanide series such as europium (Eu) ion, terbium (Tb) ion, samarium (Sm) ion, neodymium (Nd) ion, dysprosium (Dy) ion.In another embodiment, rare-earth luminescent material is that one or several in rare-earth luminescent material containing the various lanthanide series such as europium (Eu) ion, terbium (Tb) ion, samarium (Sm) ion, neodymium (Nd) ion, dysprosium (Dy) ion load to the rare-earth fluorescent microballoon that microballoon is formed.Rare-earth luminescent material is loaded to the stability that microballoon can further improve fluorescence.
Although antibody quantum dot-labeled is separately highly sensitive, the range of linearity is not good, is presented as that high level detects inaccurate.Although the antibody of independent rare-earth luminescent material mark possesses the good range of linearity, sensitivity haves much room for improvement, and is presented as that low value detects inaccurate.The utility model coupling quantum dot and rare-earth luminescent material, quantum dot-labeled thing is conducive to the detection of low value to reach the requirement of sensitivity, and rare-earth luminescent material label makes the range of linearity detected can cover high level region.
Sample detection district 4 has spaced detection zone 9 and quality control band 10, and wherein detection zone 9 is fixed with the second antibody of anti-Procalcitonin, quality control band 10 is fixed with the antibody of against murine IgG.Distance between detection zone 9 and quality control band 10 can between 0.05cm to 0.8cm.In one embodiment, be interposed between between detection zone 9 and quality control band 10 between 0.1cm to 0.6cm, preferably between 0.3cm to 0.5cm.
Suction zones 5 can be made up of the material being selected from by velveteen, glass, is preferably made up of velveteen.
The entire length of test strips is between 8cm to 10cm, and overall width, between 0.2cm to 0.5cm, preferably between 0.2cm to 0.3cm, most preferably is 0.3cm.Test strips of the present utility model is being provided sensitivity and while detecting the range of linearity, can reduced the consumption of antibody, greatly saved production cost by the length and/or width reducing test strips.
Fig. 2 is the side-looking structural representation of test strips of the present utility model.No longer repeated description is carried out to content identical with Fig. 1 in Fig. 2.
Test strips of the present utility model has at least following plurality of advantages:
1) problem that the low value sensitivity that the coupling of quantum dot and rare-earth luminescent material label overcomes existence in the detection of current Procalcitonin cannot take into account with the detection range of linearity;
2) independent sample reception area and being designed with of two analyte binding regions help improve Procalcitonin detection sensitivity; With
3) test strips structure is simple, and material therefor wide material sources are cheap, is applicable to very much Procalcitonin detection large-scale promotion application clinically.
Embodiment
Following examples for illustration of the utility model, but should not be construed as and are limited to embodiment set forth herein.
In following embodiment, described Procalcitonin first antibody, Procalcitonin second antibody, dynamics, quantum dot, rare-earth europium fluorescent microsphere, europium oxide (Eu
2o
3), 4,4'-bis-(1,1', 2,2', 3, fluoro-4', the 6'-acetyl butyryl of 3'-seven-6'-base)-chlorine sulphonyl-ortho-terphenyl (BHHCT), 2-(N-morpholine) ethyl sulfonic acid (MES), carbodiimide (EDC), N-hydroxy-succinamide (NHS), bovine serum albumin(BSA) (BSA), Tween-20, trehalose, Superdex200 filler, glass fibre element film, polyester film, nitrocellulose filter, high-intensity water absorbent paper is commercially available prod.
The preparation method of the reagent strip of described use in conjunction quantum dot and rare-earth luminescent material is:
1) preparation in sample reception district
Glass fibre element film or polyester film are put into the pretreatment fluid (0.1M containing 1%BSA and 0.1%Tween-20, boric acid-the borate buffer solution of pH8.0-8.6 or the 0.05M containing 1%BSA and 0.1%Tween-20, the Tris-HCl damping fluid of pH7.4-8.2) middle after immersion treatment 3-5 hour, in 35-39 DEG C of air dry oven, dry 3-5 hour.
2) preparation of the first analyte binding regions
The pre-service of A, the first analyte binding regions
Glass fibre element film or polyester film are put into the pretreatment fluid (0.1M containing 1%BSA and 0.1%Tween-20, boric acid-the borate buffer solution of pH8.0-8.6 or the 0.05M containing 1%BSA and 0.1%Tween-20, the Tris-HCl damping fluid of pH7.4-8.2) middle after immersion treatment 3-5 hour, in 35-39 DEG C of air dry oven, dry 3-5 hour.
The preparation of B, quantum dot-labeled antibody
Use 0.05M, 2-(N-morpholine) ethyl sulfonic acid (MES) activation buffer of pH4.5-5.0 washs the quantum dot containing carboxylic group in modified surface, adding carbodiimide (EDC) and N-hydroxy-succinamide (NHS) makes the two final concentration be 15-60mmol, room temperature reaction 20-30 minute, abundant washing quantum dot, with 0.05M, the Procalcitonin first antibody that same buffer was dialysed is added after boric acid-borate buffer solution redissolution of pH8.0-8.6, the mass ratio of first antibody and quantum dot is made to be 1:5 to 1:25, room temperature reaction is after 2 hours, add the 0.02M containing 10%BSA, the phosphate buffer room temperature of pH7.2-7.6 closes 30 minutes, abundant washing quantum dot, with the 0.05M containing 1%BSA and 0.1%Tween-20, the conserving liquid of the Tris-HCl damping fluid of pH7.4-8.2 redissolves to original volume.
The preparation of C, the first analyte binding regions
The quantum dot-labeled antibody prepared by this part step B uses and quantitatively sprays film instrument with on the plain film of the glass fibre that 2 μ l/cm-8 μ l/cm even application are pretreated in above-mentioned steps A or polyester film, in 35-39 DEG C of air dry oven, dry 2-4 hour, add drying agent and seal up for safekeeping for subsequent use.
3) preparation of the second analyte binding regions
The pre-service of A, the second analyte binding regions
Glass fibre element film or polyester film are put into the pretreatment fluid (0.1M containing 1%BSA and 0.1%Tween-20, boric acid-the borate buffer solution of pH8.0-8.6 or the 0.05M containing 1%BSA and 0.1%Tween-20, the Tris-HCl damping fluid of pH7.4-8.2) middle after immersion treatment 3-5 hour, in 35-39 DEG C of air dry oven, dry 3-5 hour.
The preparation (1) of B, rare-earth luminescent material labelled antibody
Eu is dissolved with 6M HCl
2o
3, and be settled to final concentration 1mg/ml with ultrapure water, then use 0.05MpH8.0NH
4hCO
3solution dilution 500 times.By BHHCT anhydrous alcohol solution to final concentration 10mg/ml.Use the carbonate mark damping fluid of 0.05-0.2M, pH9.0-9.5 to Procalcitonin first antibody dialysis 4-6 time, or ultrafiltration centrifugation is washed 4-6 time, adjustment concentration is to 0.25mg/ml.Add in first antibody solution by BHHCT ethanol solution with the ratio of volume ratio 1:200, room temperature lucifuge continues mixing reaction 1-3 hour.Use 0.05M pH8.0NH
4hCO
3solution desalination.Use Superdex200 filler purifying bond in 1*30cm post, with 0.1%BSA solution equilibria 1-3 hour, with 0.05M Tris-HCl wash-out, flow velocity is 1ml/min.Protein peak is collected, with 0.22 μm of filter aseptic filtration according to 280nm absorbance.Dilute 20 times with 0.05M Tris-HCl again, add Eu afterwards
3+nH
4hCO
3solution, the ratio being 1:5 to 1:15 according to volume ratio is added, and room temperature lucifuge continues mixing reaction 1-2 hour.Clean with 0.05M Tris-HCl with ultrafiltration centrifugation and be concentrated into antibody concentration and be greater than 5mg/ml, for subsequent use.
The preparation (2) of C, rare-earth luminescent material labelled antibody
Use 0.05M, the rare-earth europium fluorescent microsphere of 2-(N-morpholine) ethyl sulfonic acid (MES) the activation buffer washing of pH4.5-5.0, adding carbodiimide (EDC) and N-hydroxy-succinamide (NHS) makes the two final concentration be 15-60mmol, room temperature reaction 20-30 minute, abundant washing rare-earth europium fluorescent microsphere, with 0.05M, the first antibody of dialysing is added after boric acid-borate buffer solution redissolution of pH8.0-8.6, the mass ratio of Procalcitonin first antibody and fluorescent microsphere is made to be 1:8 to 1:60, room temperature reaction is after 2 hours, add the 0.02M containing 10%BSA, the phosphate buffer room temperature of pH7.2-7.6 closes 30 minutes, abundant washing rare-earth europium fluorescent microsphere, with the 0.05M containing 1%BSA and 0.1%Tween-20, the conserving liquid of the Tris-HCl damping fluid of pH7.4-8.2 redissolves to original volume.
The preparation of D, the second analyte binding regions
The rare-earth luminescent material labelled antibody prepared in this part step B or step C is used and quantitatively sprays film instrument with on the plain film of the glass fibre that 2 μ l/cm-8 μ l/cm even application are pretreated in above-mentioned steps A or polyester film, in 35-39 DEG C of air dry oven, dry 2-4 hour, add drying agent and seal up for safekeeping for subsequent use.
4) preparation of detection zone
The preparation of A, detection zone: use the coating buffer (0.01-0.02M containing 0.1-10% trehalose, the Tris-HCl damping fluid of pH7.4-8.2) Procalcitonin second antibody is diluted to the concentration of 0.2mg/ml-4mg/ml, use quantitatively spray film instrument with 1.2 μ l/cm even application on nitrocellulose filter, in 35-39 DEG C of air dry oven, dry 2-4 hour.
The preparation of B, quality control band: use the coating buffer (0.01-0.02M containing 0.1-10% trehalose, the Tris-HCl damping fluid of pH7.4-8.2) anti-mouse IgG is diluted to the concentration of 0.5mg/ml-3mg/ml, use quantitatively spray film instrument with 0.8 μ l/cm even application on nitrocellulose filter, in 35-39 DEG C of air dry oven, dry 2-4 hour.
The preparation of C, detection zone: with the confining liquid (0.01-0.02M containing 1-10%BSA and 1-10% trehalose, the Tris-HCl damping fluid of pH7.4-8.2) by the cellulose nitrate membrane closure 1-2 hour containing detection zone and quality control band, take out in rearmounted 35-39 DEG C air dry oven and dry 2-4 hour, envelope is for subsequent use.
5) assembling of test strips
Be less than 30% in humidity, under temperature 20-30 DEG C of condition, carry out the assembling of reagent strip.Base plate selects PVC material, connects in turn and the partly overlapping sample reception district of adjacent regions, the first analyte binding regions, the second analyte binding regions, detection zone and suction zones in the direction of base plate the same face.When detection zone covers base plate, the position of detection zone is near the second analyte binding regions, and the position of quality control band is near suction zones.Suction zones is high-intensity water absorbent paper.Be cut into test strips after assembling, and be assembled in reagent card.
6) mensuration of calibration object and measuring samples
The standard items of 100 μ l or measuring samples are joined well, carries out immunochromatography reaction, after 10-15 minute, reagent card is placed in special fluorescence detector, carry out quantitative measurement by the size reading fluorescence signal.
Above embodiment is only in order to the citing done clearly is described, the restriction not to embodiment.
Claims (9)
1. detect a test strips for Procalcitonin, it is characterized in that, comprise the ingredient that following order overlaps successively:
A) for the sample reception district of sample reception,
B) be coated with by the first analyte binding regions of the first antibody of quantum dot-labeled anti-Procalcitonin,
C) the second analyte binding regions of the first antibody of the anti-Procalcitonin marked by rare-earth luminescent material is coated with,
D) have the sample detection district of spaced detection zone and quality control band, wherein said detection zone is fixed with the second antibody of anti-Procalcitonin, described quality control band is fixed with the antibody of against murine IgG, and
E) suction zones.
2. test strips as claimed in claim 1, it is characterized in that, described test strips comprises base plate further, and wherein said sample reception district, the first analyte binding regions, the second analyte binding regions, sample detection district and suction zones are bonded on base plate and also sequentially overlap successively.
3. test strips as claimed in claim 1, it is characterized in that, described quantum dot is microspheres form and has the particle size range of 2nm-30nm, and described quantum dot is selected from following group: CdTe, CdSe, PbSe, InP and GaN.
4. test strips as claimed in claim 1, it is characterized in that, described second analyte binding regions is coated with microballoon further, and wherein said micro-ball load has described rare-earth luminescent material and described first antibody.
5. test strips as claimed in claim 4, it is characterized in that, the particle size of described microballoon is 50nm-400nm.
6. test strips as claimed in claim 5, it is characterized in that, the particle size of described microballoon is 100nm-300nm.
7. test strips as claimed in claim 6, it is characterized in that, the particle size of described microballoon is 100nm or 300nm.
8. test strips as claimed in claim 1, is characterized in that, be interposed between 0.3cm to 0.5cm between described detection zone and described quality control band.
9. test strips as claimed in claim 1, it is characterized in that, the width of described test strips is between 0.2cm to 0.5cm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520103122.3U CN204405680U (en) | 2015-02-12 | 2015-02-12 | Detect the test strips of Procalcitonin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201520103122.3U CN204405680U (en) | 2015-02-12 | 2015-02-12 | Detect the test strips of Procalcitonin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204405680U true CN204405680U (en) | 2015-06-17 |
Family
ID=53429530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520103122.3U Expired - Fee Related CN204405680U (en) | 2015-02-12 | 2015-02-12 | Detect the test strips of Procalcitonin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN204405680U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105548567A (en) * | 2016-01-18 | 2016-05-04 | 武汉菲恩生物科技有限公司 | Kit for time resolution fluorescent quantitative detection on PCT |
| CN108535486A (en) * | 2018-02-11 | 2018-09-14 | 北京华海骏业科技发展有限公司 | A kind of chloramphenicol immunofluorescence assay method based on europium label |
-
2015
- 2015-02-12 CN CN201520103122.3U patent/CN204405680U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105548567A (en) * | 2016-01-18 | 2016-05-04 | 武汉菲恩生物科技有限公司 | Kit for time resolution fluorescent quantitative detection on PCT |
| CN108535486A (en) * | 2018-02-11 | 2018-09-14 | 北京华海骏业科技发展有限公司 | A kind of chloramphenicol immunofluorescence assay method based on europium label |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN204405678U (en) | For the test strips of joint-detection cardiac muscle troponin I-myoglobins-creatine kinase isozyme | |
| CN204228717U (en) | Procalcitonin quantitatively detects fluorescence immune chromatography reagent card | |
| EP1787121B1 (en) | Lateral flow system and assay | |
| US8003407B2 (en) | Lateral flow system and assay | |
| CN108080042A (en) | Micro-fluidic chip of binding time resolved fluorometric technology and its preparation method and application | |
| CN102305858B (en) | Kit for detecting procalcitonin | |
| CA2568252A1 (en) | Quantitative lateral flow system and assay | |
| CN102023211A (en) | Immunochromatographic test strip for full quantitative detection of C-reactive protein and preparation method thereof | |
| CN105259164A (en) | Micro-fluidic chip for multi-object quantitative detection based on magnetic particle chemiluminescence | |
| CN102539785A (en) | Fluorescent immunochromatography method for whole quantitative detection of C-reactive protein and reagent kit thereof | |
| CN103149360A (en) | Multi-functional quick fluorescence immunoassay test method using functional substrate as media and using single color and multi-color quantum dots as mark | |
| CN102520194A (en) | Fluorescence immunochromatographic assay method for quantitatively detecting heart fatty acid binding protein and kit for quantitatively detecting same | |
| CN107449898B (en) | Kanamycin residue fluorescence immunochromatographic test paper and preparation method thereof | |
| CN103487578A (en) | CRP (C-reactive protein)/PCT (procalcitonin) combined diagnosis test paper and preparation method thereof | |
| CN104076140A (en) | Construction and application of chemiluminiscence-colloidal gold immunochromatography test paper | |
| CN102565423A (en) | Fluorescence immunochromatographic assay and kit for quantitatively detecting N-terminal pro brain natriuretic peptide | |
| CN105242047A (en) | Aflatoxin B1 graphene oxide immunochromatographic test strip and application thereof | |
| CN204405680U (en) | Detect the test strips of Procalcitonin | |
| CN103575902B (en) | A kind of time-resolved fluorescence method four comprehensive detection oophoroma kits and application thereof | |
| CN105195243A (en) | Magnetic particulate chemiluminescent micro-fluidic chip for quantitatively detecting myohemoglobin | |
| CN105891463A (en) | Beta-HCG quantitative detection kit based on nanometer magnetic particle time resolution fluorescence | |
| CN102520193A (en) | Fluorescence immunochromatographic assay and kit for quantitative detection of human cardiac troponin I (cTnI) | |
| CN204405679U (en) | C reactive protein detection test strips and test card | |
| CN109211869A (en) | A kind of micro-fluidic fluorescence immunoassay chip of rapid quantitative detection d-dimer | |
| CN101587071A (en) | Fluorescence immunoassay method of using zinc oxide quantum dots to mark antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180607 Address after: 225300 Taizhou, Jiangsu, China, west side of Tai Chi Road, China's medicine, building G59, 63 to three, west of Lu Jia Lu. Patentee after: JIANGSU DAJUN BIOTECHNOLOGY Co.,Ltd. Address before: 100176 Beijing Daxing District Hongda North Road 12 innovation building B block 3 District 210 Patentee before: ABZYMO BIOSCIENCES Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150617 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |